Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


50P - Transcriptomic Analysis of Host Immune Response for Precision Drug Prediction for SARS-CoV-2 Infected Patients- An Evidence-Based Approach


06 Oct 2021




Arwa Bohra


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


A. Bohra

Author affiliations

  • All India Institute of Medical Sciences Bhopal, Bhopal/IN

Abstract 50P


SARS-CoV-2 Virus can trigger severe pneumonia and lead to acute respiratory distress syndrome. Data from clinical, in vitro, and in vivo suggest that virus-induced cytokine dysregulation is a contributory factor to the pathogenesis. Drugs targeting the same are being tried.


To obtain a better understanding of the molecular events, we studied the transcriptome of infected macrophages and obtained a list of incriminated pathways using Gene Set Enrichment Analysis. Co-expression gene analysis was further used to predict drug targets.


Immune system, hemostasis, RNA metabolism, cellular response to external stimuli, vesicle- mediated transport, cell cycle mechanisms, DNA replication, and repair are upregulated. Interferon alpha, beta, and gamma are upregulated. IL-1,6,10, 13, TNF NF-KB are upregulated. Signaling by non-receptor tyrosine kinase, NOTCH, Sonic Hedgehog, lLeptin, MAP kinase-6, 4, and estrogen-mediated signaling are increased. Olfactory sensation, transmission across chemical synapses, and sperm motility appear to be downregulated. Disease host signature has resemblance with cystic fibrosis, thrombophilia, leishmania, influenza, CMV, HIV and SARS infection, and diseases of programmed cell death like neurodegenerative diseases. We have predicted 24 precise drugs which can be explored in clinical trials of SARS-CoV 2 treatment.


Our study provides important mechanistic insights into the understanding of SARS-CoV-2 viral pathogenesis and the multi-faceted host immune responses.

Legal entity responsible for the study

AIIMS Bhopal.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.